"Nacida para servir, la Clínica Adventista Belgrano ha mantenido vivos los objetivos fundacionales de educar para la salud, prevenir y principalmente asistir al paciente mediante la prestación de servicios médicos calificados y actuales. Pretendemos brindar un servicio de alta calidad basado en el conocimiento de la ciencia, la aplicación de tecnología y la esperanza y fe en Dios. Nuestra institución cuenta con un plantel de reconocida calidad profesional, permanentemente actualizado con varias especialidades referentes. Motivados a brindar la mejor atención personal al paciente, la individualidad y trascendencia en lo físico, mental y espiritual ocupa el centro de toda nuestra consideración y acción asistencial."

During the past decade, Clínica Adventista Belgrano conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 17 clinical trials were completed, i.e. on average, 45.9% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 15 clinical trials were completed. i.e. 88.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clínica Adventista Belgrano" #1 sponsor was "Eli Lilly and Company" with 12 trials, followed by "Janssen Research & Development, LLC" with 10 trials sponsored, "Amgen" with 2 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Actelion" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clínica Adventista Belgrano" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Clínica Adventista Belgrano" are "Systemic Lupus Erythematosus" (6 trials), "Ulcerative Colitis" (3 trials), "Breast Cancer" (2 trials), "COVID-19" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "Clínica Adventista Belgrano" in a lesser frequency.

Most popular intervention types in "Clínica Adventista Belgrano" are "Drug" (32 trials), "Other" (6 trials), "Biological" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Baricitinib" (4 trials), "Etrasimod" (3 trials), "Abemaciclib" (2 trials) and "Guselkumab Dose 1" (2 trials). Other intervention names were less common.

The vast majority of trials in "Clínica Adventista Belgrano" are 35 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Clínica Adventista Belgrano". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 17 completed trials in Clínica Adventista Belgrano, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Clínica Adventista Belgrano, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".